Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

The medical center is at the forefront of research in Non-Small Cell Lung Cancer (NSCLC), focusing on innovative therapies and treatment combinations to improve patient outcomes. The center's research includes evaluating the efficacy of various targeted therapies and immunotherapies, often in combination with chemotherapy, to address different genetic mutations and biomarkers associated with NSCLC.

• HER2 mutations
• PD-L1 high expression
• KRAS G12C mutation
• ALK-positive NSCLC

By exploring these diverse therapeutic avenues, the center aims to enhance progression-free survival and overall survival rates for patients with advanced stages of NSCLC.

Research at the center also extends to Small Cell Lung Cancer (SCLC), with a focus on both extensive-stage and limited-stage conditions. The center is investigating the potential of combining immunotherapies with traditional chemotherapies to improve treatment efficacy and patient survival rates.

• Extensive-stage SCLC
• Limited-stage SCLC

These studies are crucial in developing new standards of care for SCLC, a cancer type known for its aggressive nature and rapid progression.

The center is a leader in targeted therapy and precision medicine, utilizing advanced diagnostic tools to identify actionable mutations in lung cancer patients. This approach allows for the customization of treatment plans based on individual genetic profiles, enhancing the effectiveness of therapies.

• EGFR mutations
• MET amplification
• ROS1 and RET rearrangements

By tailoring treatments to the genetic makeup of tumors, the center is paving the way for more personalized and effective cancer care.